About
Ericare

Research & Development of Innovative Treatments in Metabolism and Cancer

Eric JANIN, M.D.   Founder/President

IMERIC (ERC 114) 
Clinical phase

IMERIC 

Immunometabolic treatment of cancer.

First in class, clinical phase1b/2, for treatment and prevention of hepatocellular carcinoma (HCC). Rare disease and orphan drug in Europe and USA.

Innovative breakthrough in research against primary liver cancer.

 

 

OXYTERIC (ERC 115) 
Preclinical phase

OXYTERIC, 

Prader-Willi Syndrome treatment.

In preclinical phase, for infants and children. New perspectives for this rare disease and orphan drug.

BERBERIC (ERC 116) 
Preclinical phase

BERBERIC

Global metabolic therapeutic management of type2 diabetes, MASH and HCC. 

I hereby consent to this data being stored and processed for the purpose of establishing contact. I know that I can revoke my consent at any time*

Please fill in the required fields
The message was sent successfully.

Get in touch

Phone: +33 601 954 114

Mail: eric.janin@ericare.com

WWW: ERICARE.COM

Adress: 9 avenue de Lavaur

31500 TOULOUSE

FRANCE

Copyright. All rights reserved.

Nous avons besoin de votre consentement pour charger les traductions

Nous utilisons un service tiers pour traduire le contenu du site web qui peut collecter des données sur votre activité. Veuillez consulter les détails dans la politique de confidentialité et accepter le service pour voir les traductions.